By Nina Owcharenko
The United States Supreme Court recently issued a decision (PHRMA v. Walsh) to allow Maine Rx, a Maine government program requiring prescription drug discounts, to move forward.
While the Court’s decision focused on matters of law, and not policy, health policy makers at the federal level and in every state of the Union should resist accepting this as an endorsement of policy and instead re-evaluate the real effects such a government pricing proposal would have on the delivery of health care.
Unintended Consequences of Maine Rx
Under the Maine Rx program, states would provide prescription drugs at a discount to residents who are without coverage by requiring pharmaceutical manufacturers to provide a rebate similar to…